Cargando…

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation

The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and deletions, which make their induction challenging. VRC01-class bNAbs not only exhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Christopher O., Schoofs, Till, Gnanapragasam, Priyanthi N.P., Golijanin, Jovana, Huey-Tubman, Kathryn E., Gruell, Henning, Schommers, Philipp, Suh-Toma, Nina, Lee, Yu Erica, Cetrulo Lorenzi, Julio C., Piechocka-Trocha, Alicja, Scheid, Johannes F., West, Anthony P., Walker, Bruce D., Seaman, Michael S., Klein, Florian, Nussenzweig, Michel C., Bjorkman, Pamela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374330/
https://www.ncbi.nlm.nih.gov/pubmed/35960796
http://dx.doi.org/10.1126/sciadv.abp8155
Descripción
Sumario:The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and deletions, which make their induction challenging. VRC01-class bNAbs not only exhibit extraordinary breadth and potency but also rank among the most highly somatically mutated bNAbs. Here, we describe a VRC01-class antibody isolated from a viremic controller, BG24, that is much less mutated than most relatives of its class while achieving comparable breadth and potency. A 3.8-Å x-ray crystal structure of a BG24-BG505 Env trimer complex revealed conserved contacts at the gp120 interface characteristic of the VRC01-class Abs, despite lacking common CDR3 sequence motifs. The existence of moderately mutated CD4-binding site (CD4bs) bNAbs such as BG24 provides a simpler blueprint for CD4bs antibody induction by a vaccine, raising the prospect that such an induction might be feasible with a germline-targeting approach.